Acarbose/orlistat - Empros PharmaAlternative Names: EMP-16-01
Latest Information Update: 21 Sep 2016
At a glance
- Originator Empros Pharma
- Mechanism of Action Amylase inhibitors; Lipase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 08 Aug 2016 Phase-II clinical trials in Obesity in Sweden (PO) (EudraCT2016-001055-50)
- 08 Aug 2016 Phase-II clinical trials in Type-2 diabetes mellitus in Sweden (PO) (EudraCT2016-001055-50)